Cryo-Cell International Overview
Valuation check: CCEL's P/E ratio is -11.62, below the Healthcare sector average of 27.42.
Get informed when a big investor buys or sells
+ Follow-11.62
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for CCEL is -11.62. That is below the Healthcare sector average of 27.42. Investors often review this figure alongside Cryo-Cell International's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CCEL currently prints -11.62 for P/E ratio, while the sector average sits near 27.42. That is roughly 142.4% below the sector mean. Large gaps often invite a closer look at Cryo-Cell International's growth, margins, and balance sheet.
A P/E ratio of -11.62 for Cryo-Cell International is not 'good' or 'bad' on its own. Compare it with the peer average (27.42) and with CCEL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CCEL's P/E ratio (-11.62), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Cryo-Cell International's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
